Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;29(6):1240-1243.
doi: 10.3201/eid2906.221862. Epub 2023 May 4.

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022

Ramona Groenheit, Philip Bacchus, Ilias Galanis, Klara Sondén, Ioana Bujila, Tatiana Efimova, Fredrik Garli, Oskar Karlsson Lindsjö, Mikael Mansjö, Elin Movert, Aleksandra Pettke, Marie Rapp, Maike Sperk, Sandra Söderholm, Karin Valentin Asin, Sarah Zanetti, Maria Lind Karlberg, Andreas Bråve, Kim Blom, Jonas Klingström

High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022

Ramona Groenheit et al. Emerg Infect Dis. 2023 Jun.

Abstract

We performed 2 surveys during 2022 to estimate point prevalences of SARS-CoV-2 infection compared with overall seroprevalence in Sweden. Point prevalence was 1.4% in March and 1.5% in September. Estimated seroprevalence was >80%, including among unvaccinated children. Continued SARS-CoV-2 surveillance is necessary for detecting emerging, possibly more pathogenic variants.

Keywords: COVID-19; Omicron; PCR; SARS; SARS-CoV-2; Sweden; coronavirus; coronavirus disease; epidemiology; point prevalence; respiratory infections; seroprevalence; symptoms; vaccines; viruses; zoonoses.

PubMed Disclaimer

Figures

Figure
Figure
Flowchart of study participant enrollment and collected and analyzed samples in a study of prevalence of SARS-CoV-2 Omicron infection despite high seroprevalence, Sweden, 2022. A) Surveys performed during March 21–25. B) Surveys performed September 26–29. Point prevalence and Omicron subvariant data from the September study was published previously (6).
See this image and copyright information in PMC

References

    1. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al.; NGS-SA consortium. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28:1785–90. 10.1038/s41591-022-01911-2 - DOI - PMC - PubMed
    1. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al.; Com-COV2 study group. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399:234–6. 10.1016/S0140-6736(21)02844-0 - DOI - PMC - PubMed
    1. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al.; OPTIC Consortium; ISARIC4C Consortium. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13. 10.1016/j.cell.2022.06.005 - DOI - PMC - PubMed
    1. Blom K, Marking U, Havervall S, Norin NG, Gordon M, García M, et al. Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Lancet Infect Dis. 2022;22:943–5. 10.1016/S1473-3099(22)00362-0 - DOI - PMC - PubMed
    1. Groenheit R, Beser J, Kühlmann Berenzon S, Galanis I, van Straten E, Duracz J, et al. Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020. BMC Infect Dis. 2022;22:861. 10.1186/s12879-022-07858-6 - DOI - PMC - PubMed

Publication types